2019-05-13T09:23:20-05:00 2018-12-31 131639826 EISNERAMPER LLP 130 NORTH 18TH STREET SUITE 3000 PHILADELPHIA PA 191032757 990 2018-01-01 460886344 TRANSCELERATE BIOPHARMA INC TRAN 4845391230 100 FOUR FALLS CORP CENTER NO 655 WEST CONSHOHOCKEN PA 19428 DALVIR GILL PHD CEO 4845391230 2019-05-10 1 HELEN M MARTIN P01330899 2158818800 64.238.150.4 2019-05-10 09:33:08 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 0EDE4F5BE59FB99924CAAEE7408372872BC47088 2018 2019-02-21 02:37:17Z DALVIR GILL PHD 100 FOUR FALLS CORP CENTER NO 655 WEST CONSHOHOCKEN PA 19428 25318445 0 X WWW.TRANSCELERATEBIOPHARMAINC.COM X 2012 DE IMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES.TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES. THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. 19 18 14 0 0 0 0 0 26133333 25100000 39247 218445 0 0 26172580 25318445 0 0 0 0 4790088 4997839 0 0 0 24485225 25893198 29275313 30891037 -3102733 -5572592 43979845 38632750 30831873 31059509 13147972 7573241 X TRANSCELERATE BIOPHARMA INC. IS DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES.THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. TRANSCELERATE EVOLVED FROM CONVERSATIONS AT VARIOUS FORUMS FOR EXECUTIVE R&D LEADERSHIP TO DISCUSS CURRENT ISSUES FACING THE INDUSTRY, AND EXAMINE SOLUTIONS FOR ADDRESSING COMMON CHALLENGES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. 0 0 23969483 25100000 THE CLINICAL DATA STANDARDS INITIATIVE DELIVERED TWO FINAL PAPERS; ONE ON STANDARDS MAINTENANCE AND VERSIONING AND ANOTHER ON CONSIDERATIONS FOR INTEGRATING STUDY DATA TABULATION MODEL (SDTM). THE CLINICAL RESEARCH ACCESS & INFORMATION EXCHANGE INITIATIVE RELEASED NEW PATIENT-FACING COMMUNICATION TEMPLATES. IN ADDITION, THEIR REGISTRY OF THE FUTURE ("ROTF") PROTOTYPE RECEIVED STRONG SUPPORT FROM MULTIPLE STAKEHOLDER GROUPS.THE CLINICAL RESEARCH AWARENESS INITIATIVE LAUNCHED THE ONE PERSON CLOSER CAMPAIGN TO RAISE AWARENESS ABOUT CLINICAL RESEARCH. THE CAMPAIGN SURPASSED EXPECTATIONS AND ACTIVATED THE GLOBAL HEALTH CARE PRACTITIONER AUDIENCE. THE COMMON PROTOCOL TEMPLATE (CPT) INITIATIVE DELIVERED RELEASE OF VERSION 5 WHICH INCLUDED NEW TA LIBRARIES, TECHNOLOGY ENHANCEMENTS AND PROTOCOL DISCLOSURE ELEMENTS; RELEASE OF VERSION 6 WHICH INCLUDES UPDATE TO CORE CONTENT, NEW LIBRARIES AND TECHNOLOGY ADVANCES; THE CPT WAS TRANSLATED INTO JAPANESE AND SOCIALIZED WITH THE PMDA AND JPMA. THE DATA MONITORING COMMITTEE INITIATIVE HAS DEVELOPED A DMC REGISTRY PROTOTYPE AND APPRENTICESHIP FRAMEWORK. THE DATACELERATE PLATFORM WENT LIVE IN MAY, WITH DATA FROM BIOCELERATE'S TOXICOLOGY DATA SHARING INITIATIVE, AND BACKGROUND CONTROL DATA WAS ADDED IN AUGUST.THE DIGITAL DATA FLOW INITIATIVE DEFINED THEIR YEAR 1 CHARTER AND OBJECTIVES WHICH INCLUDES A WORKING PARTNERSHIP WITH CDISC. THE ELABELS INITIATIVE PUBLISHED THEIR PAPER, THE NEAR-TERM VIABILITY AND BENEFITS OF ELABELS FOR PATIENTS, CLINICAL SITES AND SPONSORS IN DIA TIRS.THE INTERPRETATION OF PV REGULATIONS INITIATIVE DELIVERED A PERSPECTIVE ON FDA IND SAFETY REPORTING REGS AND PUBLICATION OF FINDINGS/CONCLUSIONS; DRAFT PAPER REGARDING REFERENCE SAFETY INFORMATION GUIDANCE AND PUBLICATION OF FINDINGS/CONCLUSIONS; IMPLEMENTATION GUIDE TO AIDE PHARMACEUTICAL MANUFACTURERS UNDERSTANDING OF FDA'S POSTMARKETING SAFETY REPORTING FOR COMBINATION PRODUCTS DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF MARCH 2018; IDENTIFIED COUNTRY LEVEL SIGNAL NOTIFICATION REQUIREMENTS AS THE NEXT REGULATION TO INTERPRET; PUBLISHED "GLOBAL PHARMACOVIGILANCE REGULATIONS: CALL FOR RE-HARMONIZATION" IN CLINICAL TRIALS. THE INVESTIGATOR REGISTRY INITIATIVE COMPLETED THEIR FINAL CORE PRODUCT REQUIREMENT RELEASE TO COMPLETE THE ORIGINAL INITIATIVE OBJECTIVES WITH 13 COMPANIES ADOPTING THE SOLUTION.THE PATIENT EXPERIENCE INITIATIVE PREPARED DRAFTS OF THE PATIENT PROTOCOL ENGAGEMENT TOOLKIT (P-PET) AND THE STUDY PARTICIPANT FEEDBACK QUESTIONNAIRE (SPFQ).THE PATIENT TECHNOLOGY INITIATIVE LAUNCHED THE SHARED INSIGHTS DATABASE WITH 13 COMPANIES SHARING BLINDED DATA RELATED TO THEIR EXPERIENCES IMPLEMENTING VARIOUS PATIENT TECHNOLOGIES. THE PLACEBO STANDARD OF CARE (PSOC) INITIATIVE EXPERIENCED GROWTH IN ADOPTION OF THE SOLUTION WITH 17 COMPANIES PARTICIPATING IN PSOC, AND PUBLISHED A MANUSCRIPT MINIMIZING PATIENT BURDEN THROUGH THE USE OF HISTORICAL SUBJECT-LEVEL DATA IN INNOVATIVE CONFIRMATORY CLINICAL TRIALS.THE PROTOCOL DEVIATION IS CURRENTLY ENGAGING WITH THE FDA AND WORKING ON DEVELOPING A FRAMEWORK AND TOOLKIT FOR IDENTIFYING AND REPORTING PROTOCOL DEVIATIONS.THE SHARED INVESTIGATOR PLATFORM INITIATIVE DELIVERED RELEASE 2.1 AND 2.2 (CRITICAL FUNCTIONALITY ALONG WITH DOCUMENT EXCHANGE AND SAFETY NOTIFICATIONS) FOR THE SHARED INVESTIGATOR PLATFORM ("SIP"); RELEASE 3.0 (CAPABILITY TO MIGRATE ALL ONGOING STUDIES AND ALLOWS FOR MASS ONBOARDING); COMPLETED THE SIP IMPLEMENTATION GUIDE TO SUPPORT ADOPTION AND THE SIP CRO PLAYBOOK TO SUPPORT THE ONBOARDING OF CRO PARTNERS.THE SITE QUALIFICATION & TRAINING INITIATIVE RELEASED NEW VERSIONS OF SEVERAL KEY FORMS AND DOCUMENTS TO BE MORE ACCESSIBLE TO INVESTIGATORS AND SITE STAFF AND MORE CLOSELY ALIGNED WITH THE CONTENT AVAILABLE ON THE SIP.THE VALUE OF SAFETY INFORMATION DATA SOURCES INITIATIVE SHARED KEY INSIGHTS WITH THE FDA, EMA, AND PMDA, IN RESPONSE TO WHICH THE EMA EXPRESSED STRONG INTEREST IN ADDRESSING THE CHALLENGE OF THE RAPIDLY INCREASING VOLUME OF ADVERSE EVENT REPORTING AT AN INTERNATIONAL AND MULTI-REGIONAL SCALE. THE TEAM PREPARED TWO PUBLICATIONS BASED ON THEIR EVIDENCE. 23969483 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 36 0 1 14 1 0 0 0 0 0 0 1 0 X 19 18 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 0 1 1 0 X ANTHONY GARGES HEAD OF FINANCE AND ADMINISTRATION 4845391235 100 FOUR FALLS CORP CENTER SUITE WEST CONSHOHOCKEN PA 19428 ELLIOTT LEVY CHAIR OF BOARD OF DIRECTOR 0.50 X 0 0 0 DAVID NICHOLSON VICE CHAIR OF BOARD OF DIR 0.50 X 0 0 0 JOHN OIDTMAN BOARD MEMBER 0.50 X 0 0 0 BADHRI SRINIVASAN BOARD MEMBER 0.50 X 0 0 0 BERNHARDT ZEIHER BOARD MEMBER 0.50 X 0 0 0 THOR VOIGT BOARD MEMBER 0.50 X 0 0 0 JOHN REED BOARD MEMBER 0.50 X 0 0 0 IRIS LOEW-FRIEDRICH BOARD MEMBER 0.50 X 0 0 0 ROBERT METCALF BOARD MEMBER 0.50 X 0 0 0 KATHRYN OWEN BOARD MEMBER 0.50 X 0 0 0 MICHELLE ROHRER BOARD MEMBER 0.50 X 0 0 0 PAUL STOFFELS BOARD MEMBER 0.50 X 0 0 0 MARTIN HOLST LANGE BOARD MEMBER 0.50 X 0 0 0 ROB SCOTT BOARD MEMBER 0.50 X 0 0 0 ROD MACKENZIE BOARD MEMBER 0.50 X 0 0 0 ROY BAYNES BOARD MEMBER 0.50 X 0 0 0 SEAN BOHEN BOARD MEMBER 0.50 X 0 0 0 TAKUKO YAMADA-SAWADA BOARD MEMBER 0.50 X 0 0 0 DALVIR GILL CHIEF EXECUTIVE OFFICER 40.00 X X 1693688 0 52371 ULO PALM CORPORATE SECRETARY 0.50 X 0 0 0 ANDREW LEE TREASURER 0.50 X 0 0 0 JANICE CHANG EXECUTIVE VICE PRESIDENT 40.00 X 514814 0 39146 JENNIFER A BURGESS EXECUTIVE DIRECTOR OF COMMUNICATIONS & ENGAGEMENT 40.00 X 316106 0 39877 CARA L RINALDI SENIOR DIRECTOR OF PORTFOLIO MANAGEMENT 40.00 X 241437 0 36028 ANTHONY GARGES HEAD OF FINANCE AND ADMINISTRATION 40.00 X 208844 0 28570 JENEEN DONADEO DIRECTOR, PROGRAM MANAGEMENT 40.00 X 230824 0 28849 DENISE REYES DIRECTOR OF PORTFOLIO MANAGEMENT 40.00 X 207081 0 11059 3412794 0 235900 12 0 1 0 ACCENTURE LLP 161 N CLARK STREET CHICAGO IL 60601 CONSULTING & IT SERVICES 7792946 COGNIZANT 211 QUALITY CIRCLE COLLEGE STATION TX 77845 IT SERVICES 6484520 KILPATRICK TOWNSEND 601 14TH STREET NW SUITE 900 WASHINGTON DC 20005 LEGAL SERVICES 2598623 PA CONSULTING GROUP INC 10 BRESSENDEN PLACE LONDON UK IT SERVICES 2036697 SLALOM LLC 821 2ND AVENUE SUITE 1900 SEATTLE WA 98104 CONSULTING & IT SERVICES 934604 23 MEMBERSHIP DUES 900099 25100000 25100000 25100000 218445 218445 25318445 25100000 0 218445 X 2300019 2300019 2180000 1066284 1113716 63086 20180 42906 284056 10419 273637 170678 59789 110889 2608134 1890955 717179 128370 128370 16744422 15858979 885443 75801 39712 36089 170520 1722 168798 4210696 4028247 182449 140035 140035 525528 263754 261774 913137 681565 231572 513 513 138868 240 138628 EXCESS COMPENSATION TAX 145674 145674 RECRUITING 49476 47040 2436 FACILITIES COSTS 38034 38034 DUES 2283 2283 1707 597 1110 30891037 23969483 6921554 0 2926545 7611789 12842533 1000110 23100000 24620000 101107 143842 14458 14458 512 0 4997301 5245162 11847 11847 43979845 38632750 5731873 4759509 25100000 26300000 30831873 31059509 X 13147972 7573241 13147972 7573241 43979845 38632750 -5572592 -2139 0 X 0 0 0 0 1 0 4202 4202 0 10256 10256 0 0 X 0 0 0 DALVIR GILL CHIEF EXECUTIVE OFFICER 594311 0 1099377 0 0 0 11000 0 41371 0 1746059 0 0 0 JANICE CHANG EXECUTIVE VICE PRESIDENT 385717 0 129097 0 0 0 11000 0 28146 0 553960 0 0 0 JENNIFER A BURGESS EXECUTIVE DIRECTOR OF COMMUNICATIONS 253041 0 63065 0 0 0 11000 0 28877 0 355983 0 0 0 CARA L RINALDI SENIOR DIRECTOR OF PORTFOLIO MANAGEM 200797 0 40640 0 0 0 0 0 36028 0 277465 0 0 0 ANTHONY GARGES HEAD OF FINANCE AND ADMINISTRATION 161978 0 46866 0 0 0 8400 0 20170 0 237414 0 0 0 JENEEN DONADEO DIRECTOR, PROGRAM MANAGEMENT 200074 0 30750 0 0 0 9290 0 19559 0 259673 0 0 0 DENISE REYES DIRECTOR OF PORTFOLIO MANAGEMENT 160776 0 46305 0 0 0 1245 0 9814 0 218140 0 0 0 PART I, LINE 3 THE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATEGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF $2.5 BILLION. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. THE INITIAL TIER I MEMBERS ARE FURTHER DEFINED AS THE "CHARTER MEMBERS." B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. C. ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION. FORM 990, PART VI, SECTION A, LINE 7A THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY-ONE (21) MEMBERS; PROVIDED THAT: (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS; (II) UP TO THREE (3) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS; (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS; (IV) ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS; AND (V) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION. THE CORPORATION'S BYLAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I AT-LARGE DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. THE ASSOCIATE MEMBER DIRECTOR SHALL BE ELECTED BY A PLURALITY VOTE OF THE ASSOCIATE MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. TRANSCELERATE DOES NOT PRESENTLY HAVE ANY ASSOICATE MEMBERS THEREFORE, THE ASSOICATE MEMBER BOARD SEAT IS CURRENTLY VACANT. EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER 1 MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS, PROVIDED HOWEVER, ASSOCIATE MEMBERS SHALL HAVE THE RIGHT TO CAST ONE (1) VOTE EACH WITH RESPECT TO THE ELECTION OF THE NOMINEE TO FILL THE ASSOCIATE MEMBER BOARD POSITION. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL. FORM 990, PART VI, SECTION B, LINE 11B THE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER OF THE CORPORATION IS REQUIRED TO ANNUALLY ACKNOWLEDGE THE CONFLICT OF INTEREST POLICY, AFFIRMING THAT SUCH PERSON HAS RECEIVED, READ AND UNDERSTANDS, AND AGREED TO COMPLY WITH THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. THE CEO APPROVES THE COMPENSATION FOR THE EXECUTIVE VICE PRESIDENT, ALONG WITH ALL OTHER KEY EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY AND OTHER CORPORATE POLICIES ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G EXTERNAL CONTRACTOR SUPPORT: PROGRAM SERVICE EXPENSES 7,634,931. MANAGEMENT AND GENERAL EXPENSES 131,595. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,766,526. PROJECT MANAGEMENT FEES: PROGRAM SERVICE EXPENSES 7,853,723. MANAGEMENT AND GENERAL EXPENSES 76,009. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,929,732. COMMUNICATIONS FEES: PROGRAM SERVICE EXPENSES 370,325. MANAGEMENT AND GENERAL EXPENSES 677,839. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,048,164. BIOCELERATE LLC 100 FOUR FALLS CORP CENTER SUITE 65 WEST CONSHOHOCKEN PA 19428 475492971 TO IMPROVE EFFICIENCIES IN PRECLINICAL RESEARCH. DE 1100000 1632801 TRANSCELERATE BIOPHARMA INC